Skye Bioscience GAAP EPS of -$0.32 misses by $0.01
Source: SeekingAlpha
2025-11-10 16:01:55 ET
More on Skye Bioscience
- Skye Bioscience, Inc. (SKYE) CBeyond Phase 2a Clinical Trial Topline Data Conference Call Transcript
- Skye Bioscience, Inc. (SKYE) Special Call - Slideshow
- Skye Bioscience: Promising Nimacimab Data Supports Buy Rating
- Skye plummets 60% on mid-stage data for nimacimab for weight loss
- Skye initiated at overweight at Evercore on obesity asset nimacimab
Read the full article on Seeking Alpha
For further details see:
Skye Bioscience GAAP EPS of -$0.32 misses by $0.01
Skye Bioscience Inc Com
NASDAQ: SKYE
SKYE Trading
-2.19% G/L:
$0.683 Last:
207,044 Volume:
$0.707 Open:
SKYE Latest News
March 10, 2026 04:01:00 pm
Skye Bioscience Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
March 05, 2026 07:00:00 am
Skye Bioscience to Announce 2025 Financial Results and Business Update on March 10, 2026
February 02, 2026 07:00:00 am
Skye Reports Positive CBeyond Phase 2a Extension Interim Study Results for Nimacimab in Combination With Semaglutide
SKYE Stock Data
$23,264,099
19,202,419
2.95%
18
N/A
Biotechnology & Life Sciences
Healthcare
US
San Diego
